["viewname_eprint_historical_projects_date" not defined]

Corbacioglu, Selim , Lode, Holger, Ellinger, Susanne, Zeman, Florian, Suttorp, Meinolf, Escherich, Gabriele, Bochennek, Konrad, Gruhn, Bernd, Lang, Peter, Rohde, Marius, Debatin, Klaus Michael, Steinbach, Daniel, Beilken, Andreas, Ladenstein, Ruth, Spachtholz, Rainer, Heiss, Peter, Hellwig, Dirk , Tröger, Anja, Koller, Michael , Menhart, Karin , Riemenschneider, Markus J. , Zoubaa, Saida, Kietz, Silke, Jakob, Marcus, Sommer, Gunhild , Heise, Tilman , Hundsdörfer, Patrick, Kühnle, Ingrid, Dilloo, Dagmar, Schönberger, Stefan, Schwabe, Georg, von Luettichau, Irene, Graf, Norbert, Schlegel, Paul-Gerhardt, Frühwald, Michael, Jorch, Norbert, Paulussen, Michael, Schneider, Dominik T., Metzler, Markus, Leipold, Alfred, Nathrath, Michaela, Imschweiler, Thomas, Christiansen, Holger, Schmid, Irene, Crazzolara, Roman, Niktoreh, Naghmeh, Cario, Gunnar, Faber, Joerg, Demmert, Martin, Babor, Florian, Fröhlich, Birgit, Bielack, Stefan, Bernig, Toralf, Greil, Johann, Eggert, Angelika, Simon, Thorsten und Foell, Juergen (2024) Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology 25 (7), S. 922-932.